Agavoside A



Compound IDCDAMM00281
Common nameAgavoside A
IUPAC name(1R,2S,4S,5\'R,6R,7S,8R,9S,12S,13S,16S,18S)-5',7,9,13-tetramethyl-16-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane]-10-one
Molecular formulaC33H52O9

Experimental data

Retention time40.803
Adduct[M+H]+
Actual mz593.373
Theoretical mz593.368
Error7.73
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score6.34

Identifiers and class information

Inchi keyDVGGLGXQSFURLP-XCVCLJGOSA-N
SmilesCC1CCC2(C(C3C(O2)CC4C3(C(=O)CC5C4CCC6C5(CCC(C6)OC7C(C(C(C(O7)CO)O)O)O)C)C)C)OC1
SuperclassPhenylpropanoids and polyketides
ClassFlavonoids

Pharmacokinetic properties

Number of descriptor values(#stars)1
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)7
Number of reactive functional groups (#rtvFG)2
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)592.768
Computed dipole moment(dipole)1.408
Total solvent accessible surface area (SASA)907.657
Hydrophobic component of SASA (FOSA)704.738
Hydrophilic component of SASA (FISA)202.919
Pie component of the SASA (PISA)0
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)1776.14
Number of hydrogen bond donors (donorHB)4
Number of hydrogen bond acceptors (accptHB)13.7
Free energy of solvation of dipole (dip^2/V)0.001116
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0301876
Globularity descriptor (glob)0.781439
Predicted polarizability in cubic angstroms (QPpolrz)60.433
Predicted hexadecane/gas partition coefficient (QPlogPC16)17.071
Predicted octanol/gas partition coefficient (QPlogPoct)33.473
Predicted water/gas partition coefficient (QPlogPw)21.093
Predicted octanol/water partition coefficient (QPlogPo/w)2.946
Predicted aqueous solubility (QPlogS)-6.516
Conformation-independent predicted aqueous solubility (CIQPlogS)-5.726
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-5.069
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)117.928
Predicted brain/blood partition coefficient (QPlogBB)-2.074
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)49.077
Predicted skin permeability, log Kp (QPlogKp)-4.587
PM3 calculated ionization potential (IP(ev))10.399
PM3 calculated electron affinity (EA(eV))-0.702
Number of likely metabolic reactions (#metab)5
Prediction of binding to human serum albumin (QPlogKhsa)0.382
Predicted qualitative human oral absorption (HumanOralAbsorption)1
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)68.314
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)141.306
Number of nitrogen and oxygen atoms (#NandO)9
Number of violations of Lipinski’s rule of five (RuleOfFive)1
Number of violations of Jorgensen’s rule of three (RuleOfThree)1

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
Q05586GRIN1Glutamate NMDA receptor; GRIN1/GRIN2BT62276SEA
P08185SERPINA6Corticosteroid binding globulinT88452SEA
P51449RORCNuclear receptor ROR-gammaT25307SwissTargetPrediction
P11413G6PDGlucose-6-phosphate 1-dehydrogenaseT63484SEA
P05230FGF1Acidic fibroblast growth factorT18639SEA
P05023ATP1A1Sodium/potassium-transporting ATPase alpha-1 chainT40800SEA
P60568IL2Interleukin-2T61698SEA
Q13224GRIN2BGlutamate [NMDA] receptor subunit epsilon 2T76414SEA
O15399GRIN2DGlutamate [NMDA] receptor subunit epsilon 4T56588SEA
Q14957GRIN2CGlutamate receptor ionotropic NMDA 2CT72595SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T62276DI0046Bacterial infection[ICD-11: 1A00-1C4Z]Q05586GRIN1
T62276DI0182HIV-infected patients with tuberculosis[ICD-11: 1B10-1B14]Q05586GRIN1
T88452DI0037Asthma[ICD-11: CA23]P08185SERPINA6
T88452DI0339Postoperative inflammation[ICD-11: 1A00-CA43]P08185SERPINA6
T88452DI0362Respiratory system disease[ICD-11: CB40-CB7Z]P08185SERPINA6
T25307DI0042Autoimmune disease[ICD-11: 4A40-4A45]P51449RORC
T25307DI0107Crohn disease[ICD-11: DD70]P51449RORC
T25307DI0238Lung cancer[ICD-11: 2C25]P51449RORC
T25307DI0275Multiple sclerosis[ICD-11: 8A40]P51449RORC
T25307DI0351Psoriasis[ICD-11: EA90]P51449RORC
T25307DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P51449RORC
T63484DI0086Chronic obstructive pulmonary disease[ICD-11: CA22]P11413G6PD
T18639DI0081Chronic arterial occlusive disease[ICD-11: BD4Z]P05230FGF1
T18639DI0102Coronary atherosclerosis[ICD-11: BA52]P05230FGF1
T40800DI0068Cardiac arrhythmia[ICD-11: BC9Z]P05023ATP1A1
T40800DI0086Chronic obstructive pulmonary disease[ICD-11: CA22]P05023ATP1A1
T40800DI0101Corneal disease[ICD-11: 9A76-9A78]P05023ATP1A1
T40800DI0175Heart failure[ICD-11: BD10-BD1Z]P05023ATP1A1
T40800DI0186Hyperhidrosis[ICD-11: EE00]P05023ATP1A1
T40800DI0243Malaria[ICD-11: 1F40-1F45]P05023ATP1A1
T40800DI0397Supraventricular tachyarrhythmia[ICD-11: BC81]P05023ATP1A1
T61698DI0275Multiple sclerosis[ICD-11: 8A40]P60568IL2
T61698DI0361Renal cell carcinoma[ICD-11: 2C90]P60568IL2
T76414DI0024Alpha-1-antitrypsin deficiency[ICD-11: 5C5A]Q13224GRIN2B
T56588DI0296Neurodegenerative disorder[ICD-11: 8A20-8A23]O15399GRIN2D
T72595DI0296Neurodegenerative disorder[ICD-11: 8A20-8A23]Q14957GRIN2C

Copyright © 2025